Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q202998> ?p ?o }
Showing triples 1 to 65 of
65
with 100 triples per page.
- Q202998 subject Q8297728.
- Q202998 subject Q8587764.
- Q202998 abstract "Zileuton (trade name ZYFLO) is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation. Zileuton is used for the maintenance treatment of asthma. Zileuton was introduced in 1996 by Abbott Laboratories and is now marketed in two formulations by Cornerstone Therapeutics Inc. under the brand names ZYFLO and ZYFLO CR. The original immediate-release formulation of zileuton, known as ZYFLO, is taken four times per day. The extended-release formulation, ZYFLO CR, is taken twice daily. Although the 600 mg immediate release tablet (Zyflo) and extended release formulation of zileuton is still available (Zyflo CR), the 300 mg immediate release tablet was withdrawn from the U.S. market on February 12, 2008.".
- Q202998 atcPrefix "none".
- Q202998 casNumber "111406-87-2".
- Q202998 chEBI "10112".
- Q202998 drugbank "DB00744".
- Q202998 fdaUniiCode "V1L22WVE2S".
- Q202998 iupacName "N-​[1-​(1-​benzothien-​2-​yl)​ethyl]-​N-​hydroxyurea".
- Q202998 pubchem "60490".
- Q202998 thumbnail Zileuton.svg?width=300.
- Q202998 wikiPageExternalLink drugInfo.cfm?id=4821.
- Q202998 wikiPageExternalLink www.zyflo.com.
- Q202998 wikiPageWikiLink Q110084.
- Q202998 wikiPageWikiLink Q127076.
- Q202998 wikiPageWikiLink Q1332167.
- Q202998 wikiPageWikiLink Q14821011.
- Q202998 wikiPageWikiLink Q14864419.
- Q202998 wikiPageWikiLink Q14890102.
- Q202998 wikiPageWikiLink Q14916181.
- Q202998 wikiPageWikiLink Q156.
- Q202998 wikiPageWikiLink Q158289.
- Q202998 wikiPageWikiLink Q16909071.
- Q202998 wikiPageWikiLink Q169219.
- Q202998 wikiPageWikiLink Q1755116.
- Q202998 wikiPageWikiLink Q1773974.
- Q202998 wikiPageWikiLink Q18247695.
- Q202998 wikiPageWikiLink Q183344.
- Q202998 wikiPageWikiLink Q186889.
- Q202998 wikiPageWikiLink Q2628787.
- Q202998 wikiPageWikiLink Q279330.
- Q202998 wikiPageWikiLink Q2823230.
- Q202998 wikiPageWikiLink Q306764.
- Q202998 wikiPageWikiLink Q35869.
- Q202998 wikiPageWikiLink Q407308.
- Q202998 wikiPageWikiLink Q407431.
- Q202998 wikiPageWikiLink Q407699.
- Q202998 wikiPageWikiLink Q417767.
- Q202998 wikiPageWikiLink Q423364.
- Q202998 wikiPageWikiLink Q424190.
- Q202998 wikiPageWikiLink Q461809.
- Q202998 wikiPageWikiLink Q467717.
- Q202998 wikiPageWikiLink Q50980.
- Q202998 wikiPageWikiLink Q60235.
- Q202998 wikiPageWikiLink Q79749.
- Q202998 wikiPageWikiLink Q8297728.
- Q202998 wikiPageWikiLink Q8587764.
- Q202998 wikiPageWikiLink Q928378.
- Q202998 wikiPageWikiLink Q9368.
- Q202998 wikiPageWikiLink Q9377.
- Q202998 atcPrefix "none".
- Q202998 casNumber "111406".
- Q202998 chebi "10112".
- Q202998 drugbank "DB00744".
- Q202998 iupacName "N-​[1-​​ethyl]-​N-​hydroxyurea".
- Q202998 pubchem "60490".
- Q202998 unii "V1L22WVE2S".
- Q202998 type ChemicalSubstance.
- Q202998 type Drug.
- Q202998 type ChemicalObject.
- Q202998 type Thing.
- Q202998 type Q8386.
- Q202998 comment "Zileuton (trade name ZYFLO) is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation. Zileuton is used for the maintenance treatment of asthma. Zileuton was introduced in 1996 by Abbott Laboratories and is now marketed in two formulations by Cornerstone Therapeutics Inc. under the brand names ZYFLO and ZYFLO CR. The original immediate-release formulation of zileuton, known as ZYFLO, is taken four times per day.".
- Q202998 label "Zileuton".
- Q202998 depiction Zileuton.svg.
